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Summary
The lymphokines interleukin 4 and interferon y (IFN-y) have been shown to play an important
role in regulation of polyclonal immunoglobulin E (IgE) and IgG2a responses in vitro and in
vivo . We demonstrate here that treatment with chemically modified ovalbumin (OA) results
in long-lived, 97-99% inhibition of allergen-specific murine IgE responses and 10 3-10 4-fold
increases in anti-OA IgG2a. Responses to unrelated antigens are not affected . Treatment with
unmodified OA under the same conditions fails to inhibit primary or secondary IgE responses
or to increase IgG2a but does lead to pronounced increases in OAspecific IgG1 production .
Glutaraldehyde-polymerized ovalbumin (OA-POL)-induced changes in IgE and IgG2a responses
are abrogated by in vivo treatment with purified monoclonal anti-IFN-y antibody (XMG 1.2),
a finding indicative of preferential IFN-y production upon exposure to chemically modified,
but not native, allergen . The results suggest the possibility that the pattern ofcytokine synthesis
elicited after exposure to protein antigens, and the resulting immune response, may be dependent
upon the form of antigen to which the individual is exposed and consequently may be subject
to manipulation .
T
he interferons are a family of proteins initially character-
ized on the basis of their capacity to confer antiviral
resistance but are now known to exhibit highly pleiotropic
function . The role ofIFN-y as a potent immunoregulatory
molecule acting on a variety of immune cell types is well
established (1) . Studies of polyclonally stimulated, in vitro
antibody responses indicate a central role for IFN-y in the
regulation ofmurine IgG2a production, which is enhanced,
and IgE responses, which are inhibited (2-4) . IL4, upon which
IgE responses are dependent, has the opposite effects sug-
gesting that these cytokines may act to reciprocally regulate
Ig isotype production in T cell-dependentimmune responses
as well (5) . Direct evidence of a role for IFN-y and 11,4 in
the regulation of IgE-dependent hypersensitivity responses
in vivo comes from the findings that IgE production is vir-
tually abolished by anti-IL-4 or anti-IL4 receptor treatment
(6, 7) and that injection of high doses of rIFN-y leads to
suppression of polyclonal IgE responses (8) .
As the pattern of cytokine production that is elicited in
response to antigenic exposure appears to play an important
role in shaping the resulting immune response, an important
objectivewould be the development of methods that would
allow activation of specific patterns of CKl synthesis . We
'Abbreviations used in this paper . CK, cytokine ; OA-POL, glutaraldehyde-
polymerized ovalbumin ; PCA, passive cutaneous anaphylaxis; RAG,
ragweed pollen extract .
have utilized chemically modified allergens in studies of
antigen-specific murine IgE responses . Treatment with glu-
taraldehyde-polymerized OA (OAPOL), consisting ofhigh
molecular weight (Mr 3.5 x 10') soluble polymers leads to
induction of IgE selective tolerance affecting both de novo
and ongoing responses (9) . In this report we demonstrate
that treatment of C57BL/6 mice with OAPOL induces a
virtually unresponsive state in whichmaximum IgE responses
are 1-3% of these observed in control mice . Concomitantly,
anti-OA IgG2a responses are elevated 1,000-10,000-fold . Our
finding that these effects on the response to unmodified al-
lergen are abrogated by in vivo administration of anti-IFN-y
mAb suggests preferential expansion ofOA-specific, IFN-y-
secreting CD4 clones in vivo by modified but not native
antigen .
The results indicate that preferential stimulation of dis-
tinct patterns of lymphokine synthesis may be possible and
that the form of antigen encounteredmay play an important
role in determining the nature of the resulting immune re-
sponse. Development of strategies that allow preferential stim-
ulation, or inhibition, of the synthesis of particular lym-
phokines would have far reaching effects on therapeutic
approaches to hypersensitivity, transplantation, autoimmu-
nity, and a variety of immunologic disorders .
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Animals.
￿
C57BL/6 mice (6-12-wk-old) and SD rats were bred
at the University of Manitoba breeding facility or were purchased
from Charles RiverCanada (St . Constant, PQ) . All animals were
maintained and used in strict accordance with the guidelines is-
sued by the Canadian Council on Animal Care.
Preparation ofChemically Modified OA .
￿
OA (Grade VI ; Sigma
Chemical Co ., St . Louis, MO) or (5x recrystallized ; ICN Bio-
medicals, Montreal, PQ) was treated with glutaraldehyde (Eastman
Kodak Co ., Rochester, NY) as follows . OA was dissolved at 25
mg/ml in sodium acetate/acetic acid buffer (0 .1 M, pH 5.3), 0.5
pH unit above its isoelectric point. Glutaraldehyde (6% in 0.15M
NaCl) was added dropwise with stirring over a period of several
minutes to obtain a final molar ratio of 200:1 GA/OA. The reac-
tion was allowed to proceed for 5 h, in order to yield high molec-
ular weight OA polymers . After extensive dialysis against borate
buffered saline (0 .1 M, pH 8.3), the solution was applied to a
BiogelA-50m (Bio-Rad Laboratories, Mississauga, ON) gel filtra-
tion column (2.5 x 90 cm) for characterization and purification .
Thepolymerized proteinwas recovered as a single sharp symmetric
peak (Ve/Vo of 1.4-1.55) eluting at an average M, of 3.5 x 10'
(Vo of Biogel A-50m is 5.0 x 107) . This preparation, designated
OA-POL, could be stored for at least 2 mo at 4°C without evi-
dence of any changes in its chemical or immunologic properties.
This method of glutaraldehyde polymerization was developed and
used throughout in preference to chemical modification carried out
at neutral pH in PBS (0.1 M) with all other reaction conditions
as above, a procedure found to yield highly heterogeneous mix-
tures of reaction products (9) .
Immunization and Treatment ofMice .
￿
Mice were immunizedby
intraperitoneal injection of 2 pg unmodified OA, DNPZ-OA,
TNPZ2-KLH, or 100 Fig of a ragweed pollen extract (RAG)
(generously provided by Drs . V Strevens, andA. Sehon, Univ. of
Manitoba, Winnipeg, Canada) adsorbed onto 2 mg Al(OH)3 ad-
juvant . OA-POL treatment consisted of a course of three 80-Fig
i.p. injections in saline given 10, 12, and 14 d before immuniza-
tion . Mice were usually bled by cardiac puncture 10 and 14 d after
primaryand 7 and 14 d after secondary immunizations . Sera were
collected and stored at -20°C until analyzed by ELISAor passive
cutaneous anaphylaxis (PCA).
Determination ofAntigen-Specific Antibody Levels .
￿
IgE anti-OA
levels were determined by 48-h PCA in female SD rats essentially
as described (10) . Means of duplicate or triplicate analyses, rarely
differing by more than one twofold dilution in repeat assays, are
presented . OA-specific murine IgG1, IgG2a, IgA, and IgM levels
were determined in an alkaline phosphatase-basedELISA calibrated
against a murine anti-OA standard (generously provided by Dr.
G. Strejan, Univ . of Western Ontario, London, Canada) . ELISA
plates (Corning 25805 ; Corning Science Products, Corning, NY)
were coated overnight with antigen (OA, DNP7-BSA or RAG)
at 200 Ag/ml in bicarbonate buffer (0.05 M, pH 9.6) . After 90-
min blocking with a 1% BSA, 0.05% Tween 20 solution, and ex-
tensive washing, serial dilutions of serum samples were incubated
for 4 h at 37°C, the plates were washed, and an excess of alkaline
phosphatase-conjugated rabbit anti-mouse IgG1, IgG2a, IgA, or
IgM (Southern Biotechnology Associates, Birmingham, AL) was
added overnight at 4°C . After washing the plates extensively,
p-nitrophenyl phosphate (Sigma Chemical Co.) wasadded as directed
by the manufacturer and the reaction was allowed to proceed for
100 min. Background control values for wells missing onecompo-
nent in turn did not exceed 0.07 absorbance units at 450nm . Results
are expressed as ELISA titers using the midpoint of the titration
curves obtained as compared to a constant internal standard run
280 Anti-interferon .y Treatment Blocks Inhibition of IgE Responses
in each assay. Each serum sample was assayed at least twice. The
isotypic specificity of each oftheantibody-enzyme conjugates used
was confirmed before use .
Determination ofRat IgG Concentrations.
￿
Determination of rat
IgG concentrations, necessary in the purification and quantification
of the rat IgG1 mAb (XMG 1.2 ; generously provided by Dr. T .
Mosmann, University of Alberta, Edmonton, Canada) specific for
murine IFN-ywas carried out as follows. ELISA plates were coated
overnight with affinity-purified goat anti-rat IgG Fc (10 jig/ml ;
Jackson ImmunoResearch Laboratories, West Grove, PA) as a cap-
ture reagent . After blocking, dilutions of tissue culture superna-
tant or fractions eluted from the ion exchange purification process
(see below) were incubated for3h at 37°C followed by incubation
with excess alkaline phosphatase conjugated goat anti-rat IgG
(Jackson ImmunoResearch Laboratories, West Grove, PA)overnight
at 4°C. Purified rat IgG (JacksonImmunoResearch Laboratories,
West Grove, PA .) was used at 2.5 x 10-z to 9.8 x 10-5 hg/ml
as astandard. The ELISAwas completed by washing and addition
of substrate as described above .
Preparation andPurification ofAnti-IFN-y mAlz
￿
Tissue culture
supernatants fromXMG1.2 (11) cultures were used directly in ini-
tial experiments after quantitation of total rat IgG present (as de-
scribed above) . In later experiments, purified antibody was prepared
by ion exchange chromatography using the Pharmacia Biopilot
system (Pharmacia Fine Chemicals, Piscataway, NJ) . Briefly, 1.5-2.5 1
ofexhausted tissue culture supernatant was dialyzed against citrate
buffer (0.01 M, pH 5.3) and applied to the Biopilot S-Sepharose
column . Citrate buffer was passed through the column until the
absorbance at 280 nm was <0.01, followed by application of an
increasing ionic strength gradient (Na Citrate 0.01 M, NaCl 0-0.8
M, pH 5 .3) . The eluted rat mAb is >85% pure as determined by
comparison of total protein present in the purified material (as esti-
mated by the absorbance at 280 nm) with the concentration of
rat IgG determined by ELISA as described above . This material,
typically at 600-1,000 Fig/ml, was used for in vivo intraperitoneal
injection .
Statistical Analysis.
￿
PCA andELISA titers were log transformed,
followingwhich geometric means were compared using unpaired
two-tailed Student's t tests .
Results
Inhibition ofIgE and IgG1 Responses.
￿
The effects of treat-
ment with saline or a course of three80-Ag injections of un-
modified OA orOAPOL on OA-specific IgE and IgG1 re-
sponses was examined . All mice were challenged at day 0
and at monthly intervals thereafter with OA in Al(OH)3 ad-
juvant . As indicated in Fig . 1, OA-specific serum IgE levels
in OA-POIrtreated mice were inhibited >98% (p < 0.0001)
in both primaryand secondary responses . More importantly,
repeated booster immunizations with OA in Al(OH)3 ad-
juvant failed to raise the capacity of these mice to generate
anti-OA IgE responses to above 3% of thoseobserved in un-
treated controls. This virtually unresponsive state persisted
in spite of the administration of four OA Al(OH)3 immu-
nizations over >10Ud. Treatmentwith unmodifiedOA under
the same conditions failed to inhibit primary or secondary
specific IgE responses and actually resulted in a marked ac-
celeration of the primary response (Fig. 1) .
OA-POL treatment resulted in increasedprimaryIgGl re-
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Figure 1. Inhibition of 1°, 2°, 3°, and 4° anti-OA IgE responses.
C57BL/6 mice were treated with saline ("), OA-POL (A), or unmodified
OA ([I) and were immunized with 2.0 kg OA in Al(OH)3 adjuvant 10 d
later and at monthly intervals thereafter. OA-specific IgE responses were
determined by PCA as described in Materials and Methods.
responses (Fig. 2). Thus, in contrast to the effects on IgE
responses (decreased by 30-80-fold), secondary IgG1 responses
were decreased by two- to eightfold. It should be noted that
unmodified OA given under the same conditions led to sub-
stantial increases in IgG1 production without inhibition of
primary or secondary IgE responses.
IgA responses were very weak in all groups (ELISA titers
ranged from <10 to 45) and were not affected by OA or OA-
POL treatment. Similarly, IgM responses although more sub-
stantial were not significantly affected (p > 0.05) by treat-
ment with either native or modified OA (data not shown) .
Enhancement ofOA-speck IgG2a Responses.
￿
Specific IgG2a
production by OAPOIrtreated mice exhibited striking in-
creases in both primary and secondary anti-OA responses (Fig.
3) . In contrast to the weak IgG2a responses of control mice,
DAY
Figure 2.
￿
Effect of treatment with OAPOL on anti-GA IgG1 responses.
C57BL/6 mice were treated with saline ("), OAPOL (A), or unmodified
OA (0) and were immunized and bled as described for Fig. 1. Data are
OA-specific ELISA titers.
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Figure 3.
￿
Enhancement ofanti-OA IgG2a responses after OAPOL treat-
ment. C57BL/6 mice were treated with saline ("), OA-POL (0), or OA
(0), immunized, and bled as described for Fig. 1. Data are OA-specific
ELISA titers.
OA-POL treated animals yielded OA-specific ELISA titers
1,000-10,000-fold higher. These increases persisted for the
duration of the experiments. In contrast, treatment with
unmodified OA did not significantly alter anti-OA IgG2a
responses.
Antigenic Specificity of OA-POL Induced Changes in Anti-
body Production. The changes in antibody production that
were induced as a consequence oftreatment with glutaralde-
hyde polymerized OA were antigen specific. Treatment of
mice with OA-POL, though capable of inhibiting IgE re-
sponses to OA or haptens conjugated to OA by >98% (Table
1), had no impact on antibody responses to unrelated allergens
(RAG) or DNP-specific antibody responses induced by this
hapten on heterologous carriers (DNP22-KLH) (Table 1).
Interestingly, anti-DNP IgG2a production in response to
DNP2-OA, though elevated in OA-POL treated mice (3-10-
fold), was markedly less enhanced than were IgG2a responses
to OA in the same mice. Thus, OA-specific: ELISA titers in
saline or OAPOL treated, DNP2-OA Al(OH)3 immunized
groups in this experiment were <5 vs. 2,400and 35 vs. 31,400
for primary and secondary anti-OA IgG2a responses, respec-
tively.
Sensitivity of OA-POLinduced Effects to In Vivo Treatment
with Anti-IFN-y mAh The effect of OAPOL treatment
on IgE, IgG2a, and to a lesser extent IgG1, responses sug-
gested that exposure to this chemically modified allergen led
to preferential induction of IFN-y productionby OA-specific
T cells. This hypothesis was tested by in vivo administration
of murine IFN-y-specific mAb, as tissue culture supernatant
(data not shown) or purified antibody (Table 2). In prelimi-
nary experiments, administration of50-900 hg purified XMG
1.2 mAb or normal rat IgG had no effect on the develop-
ment of IgE, IgG1, or IgG2a responses in normal OA
(Al(OH)3)-primed C57BL/6 mice (our unpublished data).
Mice were treated with a standard course of three OA-
POL injections or saline 10, 12, and 14 d before immuniza-C57BL/6 mice (three/group) were injected with 80 ug OA-POL or nothing 14, 12, and 10 d before immunization with DNPZ-OA [1 Wg in
Al(OH)3], DNP22-KLH [2 jig in Al(OH)3] or RAG [100 !Ag in Al(OH)3] . All mice were boosted with identical amounts of antigen in Al(OH)3
on day 28 . Peak primary and secondary hapten-specific or RAG-specific antibody levels were determined as described in Materials and Methods .
Data are PCA titers (IgE) or ELISA titers (IgG1, and IgG2a) .
Table 2.
￿
OA-POL-induced Inhibition of IgE Responses Is Reversed by Anti-IFN-y mAb
Mice were injected with 80 Itg OA-POL or nothing 14, 12, and 10d before immunization withOA [2 Fcg in Al(OH)3] . On the day of immuniza-
tion and the two successive days (day 0, 1, 2) or day 3, 4, 5, OA-POL-treated groups were treated with 200,ug/d of purified XMG 1.2 anti-IFN-y
mAb or normal rat IgG (not shown) . Mice were bled at the times indicated and OA-specific antibody production was determined by ELISA (IgG1,
IgG2a) or PCA (IgE) . Data shown are from one of two replicate experiments carried out with purified anti-IFN-y .
tion with OA in Al(OH)3 (day 0) . On days 0, 1, and 2 or
3, 4, and 5, mice were treated with a 200-14g/injection (in-
traperitoneally) of purifiedXMG 1.2 mAb or polyclonal rat
IgG as control . As previously, OA-specific IgE production
was strongly inhibited after OA-POL treatment . Adminis-
tration of anti-IFN-y mAb virtually abolished this inhibi-
tion . Similarly, anti-OA IgG2a increases induced byOAPOL
treatment were greatly diminished after administration ofthe
mAb soon after immunization . Anti-IFN-y treatment had
significantly less impact on both IgE and IgG2a responses
when given 3, 4, and 5 d after immunization . IgG1 responses
were not significantly affected under the conditions tested.
These results support a role for IFN-y induction as the mech-
anism responsible for the antigen-specific changes in antibody
production which occur after treatment with OA-POL .
Discussion
Our major finding is that treatment of mice with appropri-
ately modified allergen in long-lived inhibition of their ca-
pacity to generate antigen-specific IgE, and pronounced in-
creases in IgG2a, responses . These changes appear to result
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from preferential induction of IFN-'y production by OA
specific lymphocytes upon exposure to OA-POL .
The potential forIFN-y to regulate IgE responses has been
the subject of intense study. Recently, direct evidence of
IFN--y's capacity to modulate polyclonal IgE, IgG1, and IgG2a
responses in vivo was obtained using anti-IFN-'y antibody
treatment or high doses (75,000 U) of rIFN-y (7, 8) . In the
present report we demonstrate a role for in vivo induction
ofIFN-y production in the manipulation of antigen-specific
responses .
Many years ago, Watanabe et al . (12) identified Ly-1 + T
cell-dependent suppression in SJL mice, which acted to in-
hibit IgE production in an isotype specific fashion . This con-
stitutive inhibition was antigen nonspecific and may have
reflected a similar, but polyclonal, activation of IFN-y produc-
tion in that strain . Indeed, the demonstration that SJL and
SJA/9 mice give normal IgE responseswhen stimulated with
LPS and appropriate cytokines suggests that the defects in
IgE responsiveness arose as a consequence of abnormalities
in T cell regulation, not B cell potential (13) .
Previous studies of IgE responses using modified antigens
have resulted in immunoregulatory patterns which are an-
Table 1 . Antigenic and Isotypic Specificity ofOA-POL Treatment
IgE IgG1 IgG2a
Response
Treatment Immunization measured d10 d35 d10 d35 d10 d35
None DNP2-OA Anti-DNP 200 1,600 1,500 65,300 640 1,200
OA-POL DNP2-OA <10 30 1,360 61,900 1,710 12,560
None DNP22-KLH Anti-DNP 80 200 5,900 119,050 1,310 4,350
OA-POL DNP22-KLH 80 200 6,150 125,000 1,620 6,500
None RAG Anti-RAG 20 80 350 34,550 10 250
OA-POL RAG 20 100 270 25,100 20 680
Treatment Immunization Anti-IFN-y
IgE
d10 d12
OA-specific
IgG1
d10
response
d12 d10
IgG2a
d12
OA - 1,280 800 14,510 34,000 15 15
OA-POL OA - 20 <10 25,700 29,100 990 1,345
OA-POL OA day 0, 1, 2 400 640 25,150 30,400 95 115
OA-POL OA day 3, 4, 5 100 80 34,000 32,100 505 525tigen specific and isotype nonspecific; IgE specific and an-
tigen nonspecific; or less commonly, antigen specific, and iso-
type specific (reviews 14, 15). In most ofthese studies IgG2a
responses were not specifically evaluated nor was a role for
IFN-y examined. However, of particular interest is the re-
cent finding by Hagen et al. (16) of preferential induction
of IFN-y synthesis upon administration of haptenated Bor-
detella pertussis.
Glutaraldehyde has previously been used to generate het-
erogeneous allergen mixtures which were examined in an-
imal and clinical studies (17-21). Although promising in terms
of enhanced safety, these preparations failed to demonstrate
marked decreases in IgE production and their mechanism of
action remains unknown. It is unclear if this reflects differ-
ences in the modification approaches used and thus the het-
erogeneity of the resultant products (22) or more basic differ-
ences in regulatory mechanisms which govern antibody
formation in human and murine systems.
The means by which an antigen-nonspecific lymphokine
regulates responses in an antigen-specific fashion is impor-
tant. There is a growing body of evidence that antigen
specificity may be mediated as a consequence of cell-cell in-
teraction rather than specificity of the lymphokine itself. In
this regard T cell receptor directed, polar release of lym-
phokines (23) provides an attractive hypothesis to explain the
results described here.
Preliminary results (our unpublished data) indicate that
changes in OA-specific IgE and IgG2a production in OA-
POIrtreated C57BL/6 mice are CD4 T cell dependent. Since
the discovery several years ago that many murine CD4 T cell
clones could be grouped into two major subsets, designated
Thl and Th2 on the basis of cytokine production and bio-
logical function (24, 25), much effort has been aimed at de-
termining if such apparently stable patterns of differentia-
tion exist in vivo (26-30). One would predict that stimulation
of Thl-like patterns would favor DTH-like or IgG2a domi-
nated responses while stimulation of Th2 would result in
IgG1 and IgE production. Our findings are consistant with
the induction of Thl-like patterns of lymphokine secretion
upon OA-POL treatment in contrast to the Th2-like pattern
induced by native OA, especially in the presence of Al(OH)3
adjuvant.
Recent evidence suggests that the distinction between the
Thl and Th2 phenotype is not as clear cut as initially ap-
peared. Studies in vitro with clones (31) and in vivo with
spleen cells from resting or antigen-primed mice (32) sup-
port the existence of additional patterns ofcytokine synthesis.
Unresolved is the question ofwhether a given T cell in vivo
can exhibit different patterns of lymphokine synthesis de-
pending on the nature of the antigenic stimulus or the con-
text in which it is presented. Thus OAPOL may be acting
not to preferentially stimulate committed OA-specific Thl
cellsin preference to Th2, but rather may steer the activation
of OA-specific CD4 T cells towards IFN-y secretion rather
than IL4/IIr5 synthesis.
The mechanism by which native or glutaraldehyde poly-
merized OA influences lymphokine expression remains un-
clear. Immune responses dominated by Thl-like or Th2-like
cytokine synthesis patterns have previously been reported for
certain parasitic infections (33, 34) and in the response to
human basement membrane collagen (35). Recent experiments
suggest an important role for the nature of APC or the
costimulatory molecules produced by them in the differen-
tial activation ofThl and Th2 clones. Thus, antigen presen-
tation by hepatic nonparenchymal accessory cells (36) sup-
ports proliferation of long term Thl and not Th2 clones,
whileT cell lines derived using hapten-modified Langerhans
cells yield almost exclusively Th2-like lines (37). OAPOL
differs markedly from native OA in terms of its antigenicity
at the B cell level, retaining only 0.5-5% of its capacity to
be bound by anti-OA antibodies (22). This suggests that the
B cell may play a markedly smaller role than other APC in
the presentation of OAPOL and may be responsible in part
for the preferential synthesis of IFN-y in vivo. Experiments
to address this issue are underway.
Our experiments do not indicate whether the effects of
IFN-y on OA-specific IgE, IgG1, and IgG2a are direct or
indirect. The increased efficacy ofanti-IFN-y treatment when
administered at and soon after OA (Al(OH)3) immuniza-
tion suggests that a major function lies in directing the com-
mitment of OA-specific B cells to IgG2a and away from
IgE/IgG1 production. At the same time there is good evi-
dencethat IFN-y, in addition to its well defined direct effects
on B cells, specifically inhibits the generation and growth
of Th2, but not Thl, clones (38) in vitro. This putative shift
in the T cell repertoire away from 1174/1175 secretion and
towards IFN-y production may be responsible for the long
lived inability of OA-POL treated mice to generate good IgE
responses, a statewhich persists for at least 1 yr and five booster
immunizations (HayGlass, K. T, R. Gieni, and W Stefura,
manuscript submitted for publication).
It has been suggested that the relative quantities of ILA
and IFN-y produced during an immuneresponse may deter-
mine the selection and magnitude of isotypes generated in
response to a given antigen (5). The present results suggest
that it may be possible, at the level of the repertoire, for us
to manipulate the response so as to steer T cell activation
towards a specific pattern of cytokine expression and conse-
quently to control the response.
We thank Dr. Tim Mosmann for generously providing the hybridoma XMG1.2 without which this study
could not have been completed. We also thank Dr. Gill Strejan for the ELISA standard, Dr. Glen Lang
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